NDA 205850 · Praxair INC
Nitrogen, Nf
Nitrogen · Inhalation
Last checked: Nov 20, 2026Latest source record: Jul 21, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Jul 21, 2013
Approved uses
1
Original approval plus efficacy supplements
Registered trials
8,399
1,747 Phase 3, 1,035 recruiting
FAERS reports
110
93 serious, 14 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 13, 2026.
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 21, 2013 Original approval · Medical Gas Letter
1 products under this application
- NITROGEN, NF · NITROGEN N/A · GAS, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nitrogen" as an intervention, any sponsor and status, largest first.
- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic LymphomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT01190930 · 9,350 participants · Start Aug 11, 2010 · Primary completion Mar 31, 2019
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Adult B Lymphoblastic Lymphoma; Ann Arbor Stage I B Lymphoblastic Lymphoma and 7 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 243 sites in all
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT01117441 · 6,136 participants · Start Jun 2010 · Primary completion Dec 31, 2021
Drug: PEG-L-asparaginase; cyclophosphamide and 14 more · For: Leukemia
Sites: Randwick, Australia; Westmead, Australia; Dornbirn, Austria · 139 sites in all
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00002582 · 6,000 participants (planned) · Start Jun 1993
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom; Glasgow, United Kingdom
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use10
- malaise9
- drug interaction7
- accidental exposure to product6
- psoriasis6
- completed suicide5
- dyspnoea5
- haemodynamic instability5
- product leakage5
- ventricular fibrillation5
- weight decreased5
- death4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 9 |
| 2017 | 13 |
| 2018 | 15 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 7 |
| 2023 | 15 |
| 2024 | 10 |
| 2025 | 4 |
| 2026 | 10 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ambient air pollution and clinical dementia: systematic review and meta-analysis.
Wilker EH, Osman M, Weisskopf MG · BMJ 2023 · Meta-Analysis, Systematic Review
- Efficacy and safety of ketoanalogue supplementation combined with protein-restricted diets in advanced chronic kidney disease: a systematic review and meta-analysis.
Chen CH, Tsai PH, Tsai WC, et al. · J Nephrol 2024 · Systematic Review, Meta-Analysis
- Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis.
de la Iglesia-García D, Huang W, Szatmary P, et al. · Gut 2017 · Meta-Analysis, Systematic Review
- Environmental risk factors for all-cause dementia, Alzheimer's disease dementia, vascular dementia, and mild cognitive impairment: An umbrella review and meta-analysis.
Jones A, Ali MU, Mayhew A, et al. · Environ Res 2025 · Meta-Analysis, Systematic Review
- Association between air pollution and allergic upper respiratory diseases: a meta-analysis.
Zhang ZQ, Li JY, Guo Q, et al. · Eur Respir Rev 2025 · Meta-Analysis, Systematic Review
- Exposure to traffic-related air pollution and risk of development of childhood asthma: A systematic review and meta-analysis.
Khreis H, Kelly C, Tate J, et al. · Environ Int 2017 · Meta-Analysis, Systematic Review
Sponsor: Praxair INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.